Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 3/20 | 0.58 |
| ▸ | MMP2 | P08253 | 13/20 | 0.58 |
| ▸ | MMP1 | P03956 | 8/20 | 0.58 |
| ▸ | MMP3 | P08254 | 8/20 | 0.58 |
| ▸ | ACE | P12821 | 5/20 | 0.57 |
| ▸ | CPA1 | P15085 | 2/20 | 0.57 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.57 |
| ▸ | MMP7 | P09237 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21294071 | 1.00 | MME (0.58) | MMEMMP2MMP1MMP3ACE | |
| SCHEMBL29656807 | 0.88 | BIRC2 (0.64) | MMP2MMP1MMP3MMP7 | |
| SCHEMBL29232996 | 0.84 | MME (0.67) | MMEMMP2MMP1MMP3ACE | |
| SCHEMBL5326614 | 0.82 | ESR1 (0.50) | — | |
| SCHEMBL29468059 | 0.82 | MME (0.60) | MMEACECPA1ACE2 | |
| SCHEMBL8371124 | 0.82 | FAAH (0.67) | — | |
| SCHEMBL443219 | 0.82 | FAAH (0.67) | — | |
| SCHEMBL29026 | 0.82 | FAAH (0.67) | — | |
| SCHEMBL4581442 | 0.82 | FAAH (0.67) | — | |
| SCHEMBL17204106 | 0.82 | FAAH (0.67) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190262287-A1 | ANTI-INFLAMMATORY COMPOSITION | NEOPHARM CO., LTD. (KR) | 2019-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190262287-A1 | ANTI-INFLAMMATORY COMPOSITION | TNF, CUTA, IL6 | MME 3285/4885MMP2 416/4885MMP1 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.